PUBLICATIONS
Prilenia Enrolls First Subject in Europe in its
PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease
28
JANUARY
2021
Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS
08
JANUARY
2021
Additional analyses of Efficacy and Safety of Pridopidine for Huntington’s Disease demonstrate positive effect on functional capacity
16
DECEMBER
2020
Prilenia Enrolls First Patients into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United State
27
OCTOBER
2020
Huntington Study Group Announces A Partnership with Prilenia Therapeutics to Conduct A Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease
17
SEPTEMBER
2020
Henk Schuring joins Prilenia as Chief Regulatory and Commercialization Officer
10
SEPTEMBER
2020
Prilenia Therapeutics raises $62.5M to fund late stage trials in HD and ALS
03
JUNE
2020
Presentation by Dr. Michael Hayden at the Jefferies
Virtual Conference
03
JUNE
2020
18
SEPTEMBER
2019
Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General
